AU2013340831B2 - Fc gamma receptor IIB variants - Google Patents

Fc gamma receptor IIB variants Download PDF

Info

Publication number
AU2013340831B2
AU2013340831B2 AU2013340831A AU2013340831A AU2013340831B2 AU 2013340831 B2 AU2013340831 B2 AU 2013340831B2 AU 2013340831 A AU2013340831 A AU 2013340831A AU 2013340831 A AU2013340831 A AU 2013340831A AU 2013340831 B2 AU2013340831 B2 AU 2013340831B2
Authority
AU
Australia
Prior art keywords
protein
seq
nucleic acid
acid sequence
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013340831A
Other languages
English (en)
Other versions
AU2013340831A1 (en
Inventor
Uwe Jacob
Thomas Pohl
Peter Sondermann
Dominik TER MEER
Reno WINTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suppremol GmbH
Original Assignee
Suppremol GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol GmbH filed Critical Suppremol GmbH
Publication of AU2013340831A1 publication Critical patent/AU2013340831A1/en
Application granted granted Critical
Publication of AU2013340831B2 publication Critical patent/AU2013340831B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
AU2013340831A 2012-10-30 2013-10-30 Fc gamma receptor IIB variants Active AU2013340831B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/663,527 2012-10-30
US13/663,527 US10028998B2 (en) 2012-10-30 2012-10-30 Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
PCT/EP2013/072741 WO2014068012A1 (en) 2012-10-30 2013-10-30 Fc gamma receptor iib variants

Publications (2)

Publication Number Publication Date
AU2013340831A1 AU2013340831A1 (en) 2015-04-30
AU2013340831B2 true AU2013340831B2 (en) 2017-11-23

Family

ID=49679480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013340831A Active AU2013340831B2 (en) 2012-10-30 2013-10-30 Fc gamma receptor IIB variants

Country Status (27)

Country Link
US (1) US10028998B2 (enExample)
EP (1) EP2914624B1 (enExample)
JP (2) JP6423351B2 (enExample)
KR (1) KR102170674B1 (enExample)
CN (1) CN104918955B (enExample)
AU (1) AU2013340831B2 (enExample)
BR (1) BR112015008815A2 (enExample)
CA (1) CA2887164C (enExample)
CL (1) CL2015001127A1 (enExample)
DK (1) DK2914624T3 (enExample)
EA (1) EA033437B9 (enExample)
ES (1) ES2628049T3 (enExample)
HR (1) HRP20170894T1 (enExample)
HU (1) HUE032786T2 (enExample)
IL (1) IL238528A (enExample)
IN (1) IN2015DN03206A (enExample)
LT (1) LT2914624T (enExample)
MX (1) MX359802B (enExample)
MY (1) MY173686A (enExample)
NZ (1) NZ706884A (enExample)
PH (1) PH12015500771B1 (enExample)
PL (1) PL2914624T3 (enExample)
PT (1) PT2914624T (enExample)
RS (1) RS56075B1 (enExample)
SG (1) SG11201502749VA (enExample)
SI (1) SI2914624T1 (enExample)
WO (1) WO2014068012A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
EA034176B1 (ru) 2013-10-16 2020-01-14 Зуппремоль Гмбх РАСТВОРИМЫЙ Fc-ГАММА РЕЦЕПТОР ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ БУЛЛЕЗНЫХ ЗАБОЛЕВАНИЙ
JP6710451B2 (ja) * 2016-03-31 2020-06-17 東ソー株式会社 改変型組換えＦｃγＲＩＩｂ
CN112423900A (zh) * 2018-06-25 2021-02-26 巴斯夫涂料有限公司 生产优化涂层的方法和使用所述方法可获得的涂层
CN111454914A (zh) * 2019-01-18 2020-07-28 嘉兴安宇生物科技有限公司 一种腺病毒快速纯化方法
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032767A1 (en) * 1998-12-03 2000-06-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RECOMBINANT SOLUBLE Fc RECEPTORS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
DE10157290A1 (de) * 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2004293184B2 (en) 2003-11-26 2010-12-16 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Substance binding human IgG Fc receptor IIb
DE602006020333D1 (de) 2005-12-13 2011-04-07 Suppremol Gmbh Multimere fc-rezeptor-polypeptide
EP1870442A1 (en) * 2006-06-19 2007-12-26 DSMIP Assets B.V. Air drying resin and composition
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
CN102131517B (zh) 2008-06-27 2014-12-17 津莫吉尼蒂克斯公司 可溶性杂合Fc γ受体和相关的方法
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032767A1 (en) * 1998-12-03 2000-06-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RECOMBINANT SOLUBLE Fc RECEPTORS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Press release by SuppreMol GmbH dated 12th April 2010, SuppreMol Initiates Phase Ib/Iia Clinical Trial With Its Lead Candidate SM101. *
Press release by SuppreMol GmbH dated 24th January 2011, SuppreMol Completes Successful Pre-IND Meeting with FDA. *

Also Published As

Publication number Publication date
JP2016503289A (ja) 2016-02-04
JP2018186833A (ja) 2018-11-29
CN104918955A (zh) 2015-09-16
IL238528A (en) 2017-07-31
MX2015005266A (es) 2015-10-26
PL2914624T3 (pl) 2017-09-29
KR20150122621A (ko) 2015-11-02
IN2015DN03206A (enExample) 2015-10-02
WO2014068012A1 (en) 2014-05-08
CA2887164C (en) 2020-12-29
EP2914624B1 (en) 2017-03-15
PT2914624T (pt) 2017-06-07
KR102170674B1 (ko) 2020-10-28
HK1209765A1 (en) 2016-04-08
IL238528A0 (en) 2015-06-30
BR112015008815A2 (pt) 2017-11-21
EA033437B9 (ru) 2020-03-19
AU2013340831A1 (en) 2015-04-30
RS56075B1 (sr) 2017-10-31
CN104918955B (zh) 2018-10-09
US20140120080A1 (en) 2014-05-01
ES2628049T3 (es) 2017-08-01
EA033437B1 (ru) 2019-10-31
NZ706884A (en) 2019-05-31
CL2015001127A1 (es) 2015-12-18
EP2914624A1 (en) 2015-09-09
US10028998B2 (en) 2018-07-24
JP6423351B2 (ja) 2018-11-14
MY173686A (en) 2020-02-15
SI2914624T1 (sl) 2017-07-31
HUE032786T2 (en) 2017-10-30
HRP20170894T1 (hr) 2017-09-08
CA2887164A1 (en) 2014-05-08
PH12015500771A1 (en) 2015-06-08
LT2914624T (lt) 2017-06-26
EA201590845A1 (ru) 2015-08-31
DK2914624T3 (en) 2017-06-26
SG11201502749VA (en) 2015-05-28
MX359802B (es) 2018-10-10
PH12015500771B1 (en) 2018-12-14

Similar Documents

Publication Publication Date Title
AU2013340831B2 (en) Fc gamma receptor IIB variants
CA2682887C (en) Bis-met histones
Kudryashova et al. Fluorescent system based on bacterial expression of hybrid KcsA channels designed for Kv1. 3 ligand screening and study
KR20200032722A (ko) 부분절단효소 내성 trem2 변이체
JP2020191860A (ja) Ｉｌ−３７バリアント
WO2016085820A1 (en) Lysosomal targeting and uses thereof
BRPI0913577A2 (pt) polipeptídeos cd83 solúveis, formulações e métodos de uso
EP3496737B1 (en) Apom-fc fusion proteins, complexes thereof with sphingosine 1-phosphate (s1p), and methods for treating vascular and non-vascular diseases
US10669324B2 (en) Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
Castellanos et al. Expression, purification, and characterization of recombinant human and murine milk fat globule-epidermal growth factor-factor 8
Lepage et al. The self-association of two N-terminal interaction domains plays an important role in the tetramerization of TRPC4
CA2735085C (en) Fc gamma iib receptor for the treatment of b cell mediated multiple sclerosis
JP4143716B2 (ja) Ａｇｅ−ｒａｇｅ拮抗剤
JPH08149981A (ja) Ｔ細胞α鎖による抗原特異的免疫制御の方法
HK1209765B (en) Fc gamma receptor iib variants
CA2217346A1 (en) Method of production of antigen-specific glycosylation inhibiting factor
EP4608863A1 (en) Rage receptor-binding molecules, conjugates thereof and their uses to detect, prevent or treat lung diseases
WO2024006576A1 (en) Mhc class ii protein constructs
Thompson et al. Preparation of recombinantly expressed T-cell Receptor-Protein α (TCRα) for structural studies
CA3246911A1 (en) Thrombopoietin Receptor Fragments and Their Uses
CA3246858A1 (en) Soluble fragments of the thrombopoietin receptor and their uses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)